Link Between Arthritis Drugs and Alzheimer Disease Risk
Researchers sought to evaluate whether there is any evidence from real-world data on treatment with tofacitinib, tocilizumab, or tumor necrosis factor and the risk for ADRD.
Researchers sought to evaluate whether there is any evidence from real-world data on treatment with tofacitinib, tocilizumab, or tumor necrosis factor and the risk for ADRD.
Researchers established the Florida Consortium for African American Alzheimer’s Disease Studies to identify genetic risk factors and novel plasma biomarkers for AD.
In a cross-sectional study, researchers compared COVID-19 infection and mortality rates from 2019 and 2020 among Medicare enrollees with Alzheimer disease and related dementias.
The long-term extension phase of the phase 3 EMERGE and ENGAGE trials evaluated the efficacy and safety of aducanumab-avwa in adults aged 50 to 85 years with early Alzheimer disease.
Adlarity is a once-weekly transdermal formulation of donepezil that is designed to be worn for 7 days with consistent adhesion.
In this drug repurposing network analysis and retrospective case-control study, an Alzheimer disease (AD) endophenotype model was made using data from large-scale amyloid or tauopathy genome-wide association studies. Drugs approved by the United States Food and Drug Administration were evaluated for their effect on the AD endophenotype.
By using animal images, the test avoids cultural or educational bias and can be used repeatedly with no learning effect.
Adlarity is a once-weekly transdermal formulation of donepezil.
The FDA has granted Breakthrough Therapy designation to gantenerumab, an anti-amyloid beta antibody, for the treatment of Alzheimer disease.
Lecanemab is an investigational anti-amyloid beta protofibril antibody.